• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Can immune reprogramming with alemtuzumab induce permanent remission in multiple sclerosis?

作者信息

Wiendl Heinz, Bourdette Dennis, Ciccarelli Olga

机构信息

From the Department of Neurology (H.W.), University of Muenster, Germany; Department of Neurology (D.B.), Oregon Health & Science University, Portland; and Department of Neuroinflammation (O.C.), UCL Institute of Neurology, University College London, UK.

出版信息

Neurology. 2017 Sep 12;89(11):1098-1100. doi: 10.1212/WNL.0000000000004381. Epub 2017 Aug 23.

DOI:10.1212/WNL.0000000000004381
PMID:28835406
Abstract
摘要

相似文献

1
Can immune reprogramming with alemtuzumab induce permanent remission in multiple sclerosis?使用阿仑单抗进行免疫重编程能否诱导多发性硬化症永久缓解？
Neurology. 2017 Sep 12;89(11):1098-1100. doi: 10.1212/WNL.0000000000004381. Epub 2017 Aug 23.
2
Bacterial and CMV pneumonia in a patient treated with alemtuzumab for multiple sclerosis.在接受阿仑单抗治疗多发性硬化症的患者中出现细菌性和巨细胞病毒肺炎。
Mult Scler Relat Disord. 2019 Jan;27:44-45. doi: 10.1016/j.msard.2018.09.031. Epub 2018 Oct 2.
3
Alemtuzumab in Multiple Sclerosis: Mechanism of Action and Beyond.阿仑单抗治疗多发性硬化症：作用机制及其他
Int J Mol Sci. 2015 Jul 20;16(7):16414-39. doi: 10.3390/ijms160716414.
4
Management of immune thrombocytopenia in multiple sclerosis patients treated with alemtuzumab: a Belgian consensus.用阿仑单抗治疗的多发性硬化症患者免疫性血小板减少症的管理：一项比利时共识。
Acta Neurol Belg. 2018 Mar;118(1):7-11. doi: 10.1007/s13760-018-0882-3. Epub 2018 Jan 27.
5
Response to: S. Sega-Jazbec et al.: "Management of infusion related reactions associated with alemtuzumab in patients with multiple sclerosis" Multiple Sclerosis and Related Disorders 2017.回应：S. 塞加 - 亚兹贝克等人：“多发性硬化症患者中与阿仑单抗相关的输液相关反应的管理” 《多发性硬化症及相关疾病》2017年。
Mult Scler Relat Disord. 2017 Oct;17:177-178. doi: 10.1016/j.msard.2017.08.001. Epub 2017 Aug 9.
6
Active CMV infection in two patients with multiple sclerosis treated with alemtuzumab.两名接受阿仑单抗治疗的多发性硬化症患者出现活动性 CMV 感染。
Mult Scler. 2017 May;23(6):874-876. doi: 10.1177/1352458516688350. Epub 2017 Feb 1.
7
Alemtuzumab (LEMTRADA) and multiple sclerosis. Biased evaluation, evidence of serious risks.阿仑单抗（利妥昔单抗）与多发性硬化症。有偏见的评估，严重风险的证据。
Prescrire Int. 2015 Mar;24(158):69.
8
Alemtuzumab for Multiple Sclerosis.阿仑单抗治疗多发性硬化症
Curr Neurol Neurosci Rep. 2016 Sep;16(9):84. doi: 10.1007/s11910-016-0685-y.
9
Listeria Meningitis Complicating Alemtuzumab Treatment in Multiple Sclerosis--Report of Two Cases.利妥昔单抗治疗多发性硬化症并发李斯特菌性脑膜炎——两例报告
Int J Mol Sci. 2015 Jun 29;16(7):14669-76. doi: 10.3390/ijms160714669.
10
Thyroid disorders in alemtuzumab-treated multiple sclerosis patients: a Belgian consensus on diagnosis and management.阿仑单抗治疗的多发性硬化症患者的甲状腺疾病：比利时关于诊断和管理的共识
Acta Neurol Belg. 2018 Jun;118(2):153-159. doi: 10.1007/s13760-018-0883-2. Epub 2018 Jan 25.

引用本文的文献

1
Risk of secondary autoimmune diseases with alemtuzumab treatment for multiple sclerosis: a systematic review and meta-analysis.来氟米特治疗多发性硬化症的安全性：系统评价和荟萃分析。
Front Immunol. 2024 Apr 16;15:1343971. doi: 10.3389/fimmu.2024.1343971. eCollection 2024.
2
Multiple Sclerosis Therapy Consensus Group (MSTCG): position statement on disease-modifying therapies for multiple sclerosis (white paper).多发性硬化治疗共识小组（MSTCG）：关于多发性硬化疾病修正疗法的立场声明（白皮书）
Ther Adv Neurol Disord. 2021 Aug 18;14:17562864211039648. doi: 10.1177/17562864211039648. eCollection 2021.
3
[Multiple sclerosis treatment consensus group (MSTCG): position paper on disease-modifying treatment of multiple sclerosis 2021 (white paper)].
[多发性硬化治疗共识小组（MSTCG）：2021年多发性硬化疾病修正治疗立场文件（白皮书）]
Nervenarzt. 2021 Aug;92(8):773-801. doi: 10.1007/s00115-021-01157-2. Epub 2021 Jul 23.
4
Efficacy of alemtuzumab over 6 years in relapsing-remitting multiple sclerosis patients who relapsed between courses 1 and 2: Post hoc analysis of the CARE-MS studies.在第 1 疗程和第 2 疗程之间复发的复发缓解型多发性硬化症患者中，阿仑单抗治疗 6 年以上的疗效：CARE-MS 研究的事后分析。
Mult Scler. 2020 Nov;26(13):1719-1728. doi: 10.1177/1352458519881759. Epub 2019 Nov 1.
5
Lymphocyte pharmacodynamics are not associated with autoimmunity or efficacy after alemtuzumab.淋巴细胞药代动力学与阿仑单抗治疗后的自身免疫或疗效无关。
Neurol Neuroimmunol Neuroinflamm. 2019 Oct 29;7(1). doi: 10.1212/NXI.0000000000000635. Print 2020 Jan.
6
Risks and risk management in modern multiple sclerosis immunotherapeutic treatment.现代多发性硬化症免疫治疗中的风险与风险管理
Ther Adv Neurol Disord. 2019 Apr 1;12:1756286419836571. doi: 10.1177/1756286419836571. eCollection 2019.
7
Pulsed immune reconstitution therapy in multiple sclerosis.多发性硬化症的脉冲免疫重建疗法
Ther Adv Neurol Disord. 2019 Mar 28;12:1756286419836913. doi: 10.1177/1756286419836913. eCollection 2019.
8
Anti-CD52 antibody treatment depletes B cell aggregates in the central nervous system in a mouse model of multiple sclerosis.抗 CD52 抗体治疗可清除多发性硬化症小鼠模型中枢神经系统中的 B 细胞聚集物。
J Neuroinflammation. 2018 Aug 11;15(1):225. doi: 10.1186/s12974-018-1263-9.